Skip to main content
IMNM
NASDAQ Life Sciences

Q3 Loss Widens to $85.8M as Cash Runway Extends Into 2028

Tom Rudovsky · Reported by BusinessWire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$19.36
Mkt Cap
$2.285B
52W Low
$14.64
52W High
$30.06
52W Position info
32% above low
Off High info
36% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

IMNM sits 32% above its 52-week low of $14.64.

Summary

Immunome posted a Q3 net loss of $85.8 million, or $0.76 per share, versus $57.5 million a year ago, as R&D jumped to $69.5 million from $49.2 million and G&A rose to $20.9 million from $10.9 million. The company ended September with $461.6 million in cash, cash equivalents and marketable securities and says that funds operations into 2028. The pipeline update is the real story: varegacestat has an FDA PDUFA date of April 28, 2027, and the EMA validated the MAA in October 2026, while IM-1021 Phase 1 data are due at ASH on December 14, 2026. Three programs are now in the clinic, with IM-1340 expected to start Phase 1 by year-end. The burn is heavy but funded, so the near-term swing factor is the varegacestat approval decision and the ASH dataset.

At the time of this announcement, IMNM was trading at $19.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $14.64 to $30.06. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: BusinessWire.


Price Chart

Share this article

Copied!

IMNM - Latest Insights

IMNM
Oct 26, 2026, 7:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $18.11
Real-time Price: $19.06 info
Change: +$0.950 (+5%) info
Market Cap: $2.252B info
IMNM
Oct 05, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $20.95
Real-time Price: $19.06 info
Change: -$1.89 (-9%) info
Market Cap: $2.252B info
IMNM
Sep 30, 2026, 7:45 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $21.72
Real-time Price: $19.06 info
Change: -$2.66 (-12%) info
Market Cap: $2.252B info
IMNM
Aug 11, 2026, 4:10 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $26.25
Real-time Price: $19.06 info
Change: -$7.19 (-27%) info
Market Cap: $2.252B info
IMNM
Aug 11, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $26.25
Real-time Price: $19.06 info
Change: -$7.19 (-27%) info
Market Cap: $2.252B info